Therefore, we knocked down TFCP2 expression using RNA interference in A375 (melanoma), HeLa (cervical adenocarcinoma), A549 (lung carcinoma), Hep3B (liver hepatocellular carcinoma), and MDA-MB-231 (triple negative breast adenocarcinoma) cells (Fig. S4) and measured FGF1 binding and SULF1 expression. This evidence concerns the gene TFCP2 and lung carcinoma.